-
Mashup Score: 1
Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma - 9 month(s) ago
Rimas V. Lukas, MD, reflects on the key points of his presentation delivered at the 2023 Best of ASCO Meeting, which comprised existing unmet needs in low-grade glioma, key efficacy and safety findings from the INDIGO trial, and the viability of vorasidenib-based combination regimens for future investigation.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rimas V. Lukas, MD, reflects on existing unmet needs in low-grade glioma, key efficacy and safety findings from the INDIGO trial, and the viability of vorasidenib-based combination regimens for future investigation. @NUFeinbergMed @ASCO #ASCO2023 #btsm https://t.co/Q3i7l2YsHV
-
-
Mashup Score: 0Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond - 9 month(s) ago
Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant and wild-type disease, and the expanding body of evidence supporting continued antibody-drug conjugate development in non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond @MSKCancerCenter @ASCO #ASCO23 #lcsm https://t.co/4qvMRV26mp
-
-
Mashup Score: 0Ofranergene Obadenovec Plus Paclitaxel Misses the Mark in Platinum-Resistant Ovarian Cancer - 9 month(s) ago
The addition of ofranergene obadenovec to paclitaxel failed to significantly improve survival outcomes compared with paclitaxel alone in patients with platinum-resistant ovarian cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ofranergene Obadenovec Plus Paclitaxel Misses the Mark in Platinum-Resistant Ovarian Cancer @UABNews @ASCO #ASCO23 #gyncsm https://t.co/kODqoY1SCF
-
-
Mashup Score: 0LITESPARK-024 Trial to Examine HIF-2α and CDK4/6 Inhibition With Belzutifan Plus Palbociclib in Advanced RCC - 9 month(s) ago
David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
LITESPARK-024 Trial to Examine HIF-2α and CDK4/6 Inhibition With Belzutifan Plus Palbociclib in Advanced RCC @harvardmed @BIDMChealth @kidneycan #KCRS23 #kcsm https://t.co/wg8h0bpbD3
-
-
Mashup Score: 1Earlier-Line Pirtobrutinib Investigation May Alter BTK Inhibitor Sequencing in CLL and MCL - 9 month(s) ago
Prioty Islam, MD, MSc, discusses findings from the BRUIN trial, highlights the potential benefits of using noncovalent BTK inhibitors instead of or before covalent BTK inhibitors in patients with MCL or CLL, and previewed ongoing clinical trials investigating this class of agents in earlier treatment lines in these populations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Earlier-Line Pirtobrutinib Investigation May Alter BTK Inhibitor Sequencing in CLL and MCL @MSKCancerCenter #leusm #lymsm https://t.co/byo56ZGbx3
-
-
Mashup Score: 0ASCO Presentations Indicate Bright Future For Immunotherapy Combinations in Soft Tissue Sarcoma - 9 month(s) ago
Jonathan C. Trent, MD, PhD, discusses data from 2 phase 2 trials of immunotherapy in soft tissue sarcoma, as well as their clinical significance.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ASCO Presentations Indicate Bright Future For Immunotherapy Combinations in Soft Tissue Sarcoma @JTrentMDPhD @SylvesterCancer #oncology https://t.co/Yuk4HlMHVT
-
-
Mashup Score: 0Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C Melanoma - 10 month(s) ago
Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
As we continue to showcase exciting research from the 2023 ASCO Annual Meeting, watch @BrianGastmanMD, of @ClevelandClinic, discuss findings from a biomarker analysis of the CheckMate76K study in patients with stage IIB/C melanoma! @ASCO #ASCO23 #melsm https://t.co/Mg1dDPmIfX https://t.co/RA2R9hBbuJ
-
-
Mashup Score: 0
The novel bifunctional fusion protein SHR-1701 combined with standard first-line treatment with the bevacizumab biosimilar BP102 and platinum-doublet chemotherapy produced high, durable responses and was deemed tolerable in patients with cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity in Cervical Cancer @ASCO #ASCO23 #gynsm https://t.co/qLpeM7jsQj
-
-
Mashup Score: 0Westin Highlights Key Clinical Trial Updates from the 2023 ASCO Annual Meeting in Gynecologic Oncology - 10 month(s) ago
Shannon Westin, MD, MPH, FACOG, expands on key clinical trial updates in gynecologic oncology shared at the 2023 ASCO Annual Meeting and highlights what she is looking forward to seeing in the future of care for patients with gynecologic malignancies.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Westin Highlights Key Clinical Trial Updates from the 2023 ASCO Annual Meeting in Gynecologic Oncology @ShannonWestin @MDAndersonNews @ASCO #ASCO23 #gynsm https://t.co/uAJX2ecWbi
-
WATCH: Anna B. Halpern, MD, OF @fredhutch, discusses key efficacy data from the phase 1/2 MANIFEST trial investigating the BET inhibitor #pelabresib plus #ruxolitinib, and highlights the agents clinical significance in patients with #myelofibrosis. https://t.co/TUUFxiVxNw